- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
5
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
5 companies
CanSino Biologics
Market Cap: HK$9.7b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$23.18
7D
-2.5%
1Y
-48.3%
Akeso
Market Cap: HK$88.1b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$93.20
7D
-9.3%
1Y
-39.7%
Innovent Biologics
Market Cap: HK$156.2b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$88.10
7D
-3.2%
1Y
-10.1%
InSilico Medicine Cayman TopCo
Market Cap: HK$24.9b
Engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
3696
HK$42.06
7D
-13.2%
1Y
n/a
WuXi XDC Cayman
Market Cap: HK$67.1b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$51.05
7D
-8.3%
1Y
-11.5%